BIOMAT Database Logo BIOMAT Database Logo

Effects of pranlukast, a leukotriene receptor antagonist, on airway inflammation in mild asthmatics. 2001

K Yamauchi, and Y Tanifuji, and L H Pan, and T Yoshida, and S Sakurai, and S Goto, and S Kuroda, and H Kobayashi, and H Inoue
The Third Department of Internal Medicine, Iwate Medical University, School of Medicine, Morioka, Japan.

To determine the anti-inflammatory actions of pranlukast, a cysteinyl leuklotriene receptor antagonist, we measured exhaled nitric oxide (NO) concentrations and eosinophil ratio in induced sputum of three groups of mild asthmatics (n = 30): treated with bronchodilators alone, with bronchodilators and inhaled steroid (beclomethasone dipropionate; 400 microg/day), and bronchodilators and pranlukast (450 mg/day). Pranlukast (450 mg/day) reduced the eosinophil ratio in the induced sputum significantly (p < 0.01) without a major effect on the concentration of exhaled NO. Pranlukast also increased values of peak expiratory flow significantly (p < 0.05). Pranlukast may be useful for mild asthmatics, in part through its ability to suppress eosinophilic airway infiltration.

UI MeSH Term Description Entries
D007249 Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function. Innate Inflammatory Response,Inflammations,Inflammatory Response, Innate,Innate Inflammatory Responses
D007958 Leukocyte Count The number of WHITE BLOOD CELLS per unit volume in venous BLOOD. A differential leukocyte count measures the relative numbers of the different types of white cells. Blood Cell Count, White,Differential Leukocyte Count,Leukocyte Count, Differential,Leukocyte Number,White Blood Cell Count,Count, Differential Leukocyte,Count, Leukocyte,Counts, Differential Leukocyte,Counts, Leukocyte,Differential Leukocyte Counts,Leukocyte Counts,Leukocyte Counts, Differential,Leukocyte Numbers,Number, Leukocyte,Numbers, Leukocyte
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002867 Chromones 1,4-Benzopyrones,Chromone,1,4 Benzopyrones
D004804 Eosinophils Granular leukocytes with a nucleus that usually has two lobes connected by a slender thread of chromatin, and cytoplasm containing coarse, round granules that are uniform in size and stainable by eosin. Eosinophil
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D001249 Asthma A form of bronchial disorder with three distinct components: airway hyper-responsiveness (RESPIRATORY HYPERSENSITIVITY), airway INFLAMMATION, and intermittent AIRWAY OBSTRUCTION. It is characterized by spasmodic contraction of airway smooth muscle, WHEEZING, and dyspnea (DYSPNEA, PAROXYSMAL). Asthma, Bronchial,Bronchial Asthma,Asthmas

Related Publications

K Yamauchi, and Y Tanifuji, and L H Pan, and T Yoshida, and S Sakurai, and S Goto, and S Kuroda, and H Kobayashi, and H Inoue
The leukotriene receptor antagonist pranlukast attenuates airway remodeling by suppressing TGF-β signaling.
February 2018, Pulmonary pharmacology & therapeutics,
K Yamauchi, and Y Tanifuji, and L H Pan, and T Yoshida, and S Sakurai, and S Goto, and S Kuroda, and H Kobayashi, and H Inoue
Effects of pranlukast, a cysteinyl leukotriene antagonist, on bronchial responsiveness to methacholine in aspirin-intolerant asthmatics treated with corticosteroids.
June 2000, Hiroshima journal of medical sciences,
K Yamauchi, and Y Tanifuji, and L H Pan, and T Yoshida, and S Sakurai, and S Goto, and S Kuroda, and H Kobayashi, and H Inoue
Decreased exhaled nitric oxide in mild persistent asthma patients treated with a leukotriene receptor antagonist, pranlukast.
December 1999, The Japanese journal of physiology,
K Yamauchi, and Y Tanifuji, and L H Pan, and T Yoshida, and S Sakurai, and S Goto, and S Kuroda, and H Kobayashi, and H Inoue
Synergistic effects of pranlukast and leukotriene B4 receptor antagonist on antigen-induced pulmonary reaction.
April 1999, European journal of pharmacology,
K Yamauchi, and Y Tanifuji, and L H Pan, and T Yoshida, and S Sakurai, and S Goto, and S Kuroda, and H Kobayashi, and H Inoue
Tubulointerstitial nephritis induced by the leukotriene receptor antagonist pranlukast.
October 1998, Chest,
K Yamauchi, and Y Tanifuji, and L H Pan, and T Yoshida, and S Sakurai, and S Goto, and S Kuroda, and H Kobayashi, and H Inoue
Churg-Strauss syndrome and the leukotriene receptor antagonist pranlukast.
November 2005, Clinical rheumatology,
K Yamauchi, and Y Tanifuji, and L H Pan, and T Yoshida, and S Sakurai, and S Goto, and S Kuroda, and H Kobayashi, and H Inoue
Therapeutic effect of pranlukast, a selective cysteinyl leukotriene receptor antagonist, on bronchial asthma.
September 1997, International archives of allergy and immunology,
K Yamauchi, and Y Tanifuji, and L H Pan, and T Yoshida, and S Sakurai, and S Goto, and S Kuroda, and H Kobayashi, and H Inoue
Clinical effects of pranlukast, an oral leukotriene receptor antagonist, in mild-to-moderate asthma: a 4 week randomized multicentre controlled trial.
March 2001, Respirology (Carlton, Vic.),
K Yamauchi, and Y Tanifuji, and L H Pan, and T Yoshida, and S Sakurai, and S Goto, and S Kuroda, and H Kobayashi, and H Inoue
Effect of pranlukast, an oral leukotriene receptor antagonist, on leukotriene D4 (LTD4) challenge in normal volunteers.
June 1997, Thorax,
K Yamauchi, and Y Tanifuji, and L H Pan, and T Yoshida, and S Sakurai, and S Goto, and S Kuroda, and H Kobayashi, and H Inoue
Pranlukast, a leukotriene receptor antagonist, inhibits interleukin-5 production via a mechanism distinct from leukotriene receptor antagonism.
February 2005, International archives of allergy and immunology,
Copied contents to your clipboard!